Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

Medical Malpractice Law & StrategyKickerFeaturesSectionsNewsLJN Newsletters

Drug & Device News

By ALM Staff | Law Journal Newsletters |
September 27, 2006

Is Drug Researcher Too Cozy With Manufacturers?

Responding to reports of possible conflicts of interest between a drug researcher at the National Cancer Institute and pharmaceutical companies, members of the House Energy and Commerce Committee in August reportedly sent a letter to the National Institutes of Health (NIH) asking for information about researchers' involvement with drug companies. (Willman, The Los Angeles Times, 8/10). There have been allegations that Thomas Walsh, the head of pediatric medical research at the National Cancer Institute, accepted consulting fees and/or research donations from drug manufacturers Merck and Fujisawa. He has also testified before government agencies on behalf of the two companies, something not generally allowed under federal law. The Congressional Committee has asked for several years' worth of Dr. Walsh's financial disclosure statements as well as documents setting out FDA policy on employees testifying on behalf of drug companies before the FDA and its advisory committees.

This premium content is locked for LJN Newsletters subscribers only

  • Stay current on the latest information, rulings, regulations, and trends
  • Includes practical, must-have information on copyrights, royalties, AI, and more
  • Tap into expert guidance from top entertainment lawyers and experts

For enterprise-wide or corporate acess, please contact Customer Service at [email protected] or 877-256-2473

Read These Next
The DOJ's Corporate Enforcement Policy: One Year Later Image

The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.

The DOJ's New Parameters for Evaluating Corporate Compliance Programs Image

The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.

Use of Deferred Prosecution Agreements In White Collar Investigations Image

This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.

Bankruptcy Sales: Finding a Diamond In the Rough Image

There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.

Compliance Officers: Recent Regulatory Guidance and Enforcement Actions and Mitigating the Risk of Personal Liability Image

This article explores legal developments over the past year that may impact compliance officer personal liability.